CL2008003184A1 - Compuestos derivados de arilindenopirimidinas antagonistas de receptores de adenosina a2a, composicion farmaceutica que los contiene y su uso en trastornos neurodegenerativos o motores tales como parkinson, mal de huntington, atrofia sistemica multiple, degeneracion corticobasal, alzheimer, depresion y ansiedad, entre otros. - Google Patents

Compuestos derivados de arilindenopirimidinas antagonistas de receptores de adenosina a2a, composicion farmaceutica que los contiene y su uso en trastornos neurodegenerativos o motores tales como parkinson, mal de huntington, atrofia sistemica multiple, degeneracion corticobasal, alzheimer, depresion y ansiedad, entre otros.

Info

Publication number
CL2008003184A1
CL2008003184A1 CL2008003184A CL2008003184A CL2008003184A1 CL 2008003184 A1 CL2008003184 A1 CL 2008003184A1 CL 2008003184 A CL2008003184 A CL 2008003184A CL 2008003184 A CL2008003184 A CL 2008003184A CL 2008003184 A1 CL2008003184 A1 CL 2008003184A1
Authority
CL
Chile
Prior art keywords
arilindenopyrimidines
huntington
neurodegenerative
adenosine
anxiety
Prior art date
Application number
CL2008003184A
Other languages
English (en)
Spanish (es)
Inventor
Brian C Shook
Paul F Jackson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2008003184A1 publication Critical patent/CL2008003184A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2008003184A 2007-10-25 2008-10-24 Compuestos derivados de arilindenopirimidinas antagonistas de receptores de adenosina a2a, composicion farmaceutica que los contiene y su uso en trastornos neurodegenerativos o motores tales como parkinson, mal de huntington, atrofia sistemica multiple, degeneracion corticobasal, alzheimer, depresion y ansiedad, entre otros. CL2008003184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
CL2008003184A1 true CL2008003184A1 (es) 2009-10-16

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003184A CL2008003184A1 (es) 2007-10-25 2008-10-24 Compuestos derivados de arilindenopirimidinas antagonistas de receptores de adenosina a2a, composicion farmaceutica que los contiene y su uso en trastornos neurodegenerativos o motores tales como parkinson, mal de huntington, atrofia sistemica multiple, degeneracion corticobasal, alzheimer, depresion y ansiedad, entre otros.

Country Status (13)

Country Link
US (1) US20090111804A1 (de)
EP (1) EP2220053B1 (de)
JP (1) JP2011500833A (de)
CN (1) CN101835760A (de)
AR (1) AR069026A1 (de)
AT (1) ATE509012T1 (de)
AU (1) AU2008316821A1 (de)
CL (1) CL2008003184A1 (de)
PA (1) PA8801401A1 (de)
PE (1) PE20091345A1 (de)
TW (1) TW200934496A (de)
UY (1) UY31421A1 (de)
WO (1) WO2009055548A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド Trop-2発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
EP1673354B1 (de) * 2003-10-03 2009-04-22 Ortho-McNeil Pharmaceutical, Inc. Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten

Also Published As

Publication number Publication date
JP2011500833A (ja) 2011-01-06
UY31421A1 (es) 2009-04-30
PE20091345A1 (es) 2009-09-24
US20090111804A1 (en) 2009-04-30
PA8801401A1 (es) 2009-05-15
AR069026A1 (es) 2009-12-23
EP2220053B1 (de) 2011-05-11
CN101835760A (zh) 2010-09-15
ATE509012T1 (de) 2011-05-15
EP2220053A1 (de) 2010-08-25
TW200934496A (en) 2009-08-16
AU2008316821A1 (en) 2009-04-30
WO2009055548A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CR9786A (es) Compuestos de bencimidazol-tiofeno
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
ECSP099490A (es) Métodos de fabricación y uso de compuestos y composiciones
SV2006002167A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol- oxindol y sus usos ref. am101791
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
UY32659A (es) Pirazinilpirazoles
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
DK1877409T3 (da) Substituerede pyrrolopyridiner, sammensætninger, der indeholder samme, fremgangsmåde til fremstilling deraf samt anvendelse deraf
CL2013002394A1 (es) Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros.
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.